Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... Read more about these developments by ...

They include U.S. government securities, municipals, mortgage and asset-backed, foreign bonds, and corporate bonds. In a well-diversified investment portfolio, highly-rated corporate bonds with ...

Novo Nordisk and Eli Lilly have filed a motion to dismiss in the MDL over Ozempic and similar drugs. The defendants are asking the court to throw out 12 of the plaintiffs' 17 claims. The ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Maybe hit the gym ? What you suggesting ? Any tips welcome (prayer emoji).' Lilly first revealed she signed up for the German version of I'm a Celebrity to the Mail's Richard Eden - and ...

Shares of Eli Lilly & Co. were headed for their worst ... Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...